Last updated: September 8, 2026
Dapagliflozin has developed into a high-growth, multi-indication franchise led by AstraZeneca’s Farxiga, while saxagliptin hydrochloride has entered a mature and declining phase led by Onglyza and fixed-dose combination products. Dapagliflozin benefits from heart-failure and chronic-kidney-disease demand beyond type 2 diabetes. Saxagliptin remains commercially relevant mainly as a low-cost DPP-4 inhibitor and as a component of Qtern, but its market position is weakened by generic competition, reimbursement pressure, and stronger GLP-1 and SGLT2 alternatives.
What are dapagliflozin and saxagliptin hydrochloride?
Dapagliflozin is a sodium-glucose cotransporter-2, or SGLT2, inhibitor. AstraZeneca markets it in the United States as Farxiga and in combination with saxagliptin as Qtern. Dapagliflozin is approved for type 2 diabetes, heart failure with reduced or preserved ejection fraction, and chronic kidney disease in defined patient populations.
Saxagliptin hydrochloride is a dipeptidyl peptidase-4, or DPP-4, inhibitor. AstraZeneca markets it as Onglyza. It is also sold in fixed-dose combinations with metformin as Kombiglyze XR and with dapagliflozin as Qtern.
| Product |
Active ingredient |
Primary company |
Main U.S. uses |
Commercial status |
| Farxiga |
Dapagliflozin |
AstraZeneca |
Type 2 diabetes, heart failure, chronic kidney disease |
Growth franchise |
| Onglyza |
Saxagliptin hydrochloride |
AstraZeneca |
Type 2 diabetes |
Mature and declining |
| Qtern |
Dapagliflozin/saxagliptin |
AstraZeneca |
Type 2 diabetes |
Niche combination |
| Kombiglyze XR |
Saxagliptin/metformin |
AstraZeneca |
Type 2 diabetes |
Mature combination |
| Qternmet XR |
Dapagliflozin/saxagliptin/metformin |
AstraZeneca |
Type 2 diabetes |
Niche combination |
The key commercial distinction is that dapagliflozin has expanded into high-value cardiovascular and renal indications. Saxagliptin remains concentrated in diabetes treatment, where lower-cost generic DPP-4 inhibitors and newer drug classes have reduced pricing power.
How has the dapagliflozin market developed?
Dapagliflozin’s market has expanded from a diabetes product into a broader cardiorenal medicine. Farxiga’s clinical positioning in heart failure and chronic kidney disease has allowed AstraZeneca to reach patients who may not have diabetes and to compete for treatment budgets outside the traditional glucose-lowering market.
AstraZeneca reported Farxiga sales of approximately $5.9 billion in 2023, compared with roughly $4.4 billion in 2022 and $3.0 billion in 2021. The product was one of the company’s largest growth drivers during that period (AstraZeneca, 2024).
| Fiscal year |
Farxiga revenue, approximately |
Year-over-year change |
| 2021 |
$3.0 billion |
N/A |
| 2022 |
$4.4 billion |
About 47% |
| 2023 |
$5.9 billion |
About 34% |
Growth has been supported by four factors:
- Wider heart-failure use across ejection-fraction categories.
- Chronic-kidney-disease adoption following positive renal-outcome data.
- Continued type 2 diabetes prescribing.
- Increasing physician familiarity with SGLT2 inhibitors as cardiorenal therapies.
The principal market constraints are class competition from empagliflozin, canagliflozin, and other SGLT2 inhibitors; payer rebate pressure; safety monitoring for genital infections and volume depletion; and the expected erosion of U.S. exclusivity.
What is the financial trajectory for saxagliptin hydrochloride?
Saxagliptin has a materially weaker financial trajectory than dapagliflozin. AstraZeneca does not report Onglyza revenue as a separate major growth line in the same way it reports Farxiga. Onglyza, Kombiglyze XR, and Qtern are generally included within broader product or regional reporting categories.
The franchise has declined because:
- DPP-4 inhibitors have lower cardiovascular and renal differentiation than SGLT2 inhibitors and GLP-1 receptor agonists.
- Saxagliptin carries a heart-failure hospitalization warning in U.S. labeling.
- Sitagliptin and linagliptin have maintained stronger physician and payer positions in the DPP-4 class.
- Generic saxagliptin and generic combination products have reduced price expectations.
- Qtern depends on a diabetes market increasingly shaped by SGLT2 monotherapy, GLP-1 therapies, and combination regimens that do not include saxagliptin.
Saxagliptin remains useful where oral administration, low hypoglycemia risk, and predictable glucose lowering are priorities. It has limited ability to command premium pricing without patent protection or a differentiated outcomes profile.
What patents protect dapagliflozin and saxagliptin?
Dapagliflozin and saxagliptin have separate patent estates. Combination-product protection is narrower than the protection for each active ingredient and is generally more vulnerable to design-around strategies.
Dapagliflozin patent estate
The original dapagliflozin compound and related glucose-transporter inhibitor patents were developed by Bristol-Myers Squibb and AstraZeneca. Key U.S. Orange Book-listed patent families have included patents covering the compound, pharmaceutical compositions, crystalline forms, and methods of treating diabetes.
The commercial relevance of the estate has shifted from basic compound protection to later-expiring formulation and method-of-use claims. The central commercial patent risk concerns the timing of generic Farxiga entry rather than the existence of early compound patents, which expired earlier.
AstraZeneca has publicly identified Farxiga as having U.S. loss-of-exclusivity exposure in the middle of the decade. Generic applicants have challenged relevant patents through Paragraph IV certifications, creating litigation and settlement risk before commercial entry (AstraZeneca, 2024; FDA, 2024).
Saxagliptin patent estate
Saxagliptin was discovered through research associated with Bristol-Myers Squibb and later commercialized by AstraZeneca. Its patent estate has included composition-of-matter, formulation, and treatment patents.
The core saxagliptin estate is older than the dapagliflozin cardiorenal estate. As a result, the active ingredient has faced earlier generic pressure. The remaining commercial protection is concentrated in specific dosage forms, combination products, and method-of-use claims.
Patent comparison
| Issue |
Dapagliflozin |
Saxagliptin hydrochloride |
| Original commercial focus |
Type 2 diabetes |
Type 2 diabetes |
| Later expansion |
Heart failure and chronic kidney disease |
Limited indication expansion |
| Commercial patent value |
High because of cardiorenal use |
Lower because core diabetes use is mature |
| Generic risk |
Significant near-term risk |
Already elevated |
| Formulation value |
Relevant for tablets and combinations |
Relevant but narrower |
| Litigation exposure |
High due to Farxiga revenue |
Lower absolute value but active in generic filings |
| Revenue sensitivity |
Multibillion-dollar franchise |
Mature, declining franchise |
When does dapagliflozin lose exclusivity?
Farxiga’s U.S. exclusivity is expected to weaken in the mid-2020s as relevant patents expire or are resolved through Paragraph IV litigation and settlements. The precise first-launch date depends on the patent claims challenged, settlement terms, and any applicable pediatric exclusivity.
The practical timeline is:
| Period |
Market event |
Commercial effect |
| 2014 onward |
Farxiga expands after U.S. approval |
Initial diabetes-led growth |
| 2020-2023 |
Heart-failure and kidney-disease indications expand |
Stronger pricing and volume |
| 2023-2025 |
Generic patent challenges intensify |
Increased discounting and contracting pressure |
| Mid-2020s |
Expected U.S. generic entry window |
Rapid erosion in diabetes volume and price |
| Post-entry |
Continued branded cardiorenal prescribing |
Partial protection for Farxiga demand |
A generic launch would not eliminate Farxiga revenue immediately. Cardiologists and nephrologists may continue to prescribe the branded product for patients stabilized on therapy, while payer formularies could move quickly to generic dapagliflozin. The magnitude of erosion will depend on whether generic manufacturers receive broad approval for the same strengths and indications, and on the number of launch competitors.
What is the Orange Book status of Farxiga, Onglyza, and Qtern?
The FDA Orange Book identifies patents and exclusivity relevant to approved drug products. Farxiga’s listing has been commercially important because of its high revenue base and multiple strengths. Onglyza’s listing has become less commercially protective as the saxagliptin market has matured. Qtern and other fixed-dose combinations depend on product-specific patents and may have a smaller defensive value than the Farxiga monotherapy estate.
Orange Book analysis should distinguish:
- Drug-substance patents.
- Drug-product and formulation patents.
- Method-of-use patents.
- Combination-product patents.
- Patents that remain listed but have limited practical enforcement value.
- Patents subject to Paragraph IV litigation or settlement restrictions.
The FDA Orange Book is the controlling public reference for listed patents, but it does not determine whether a patent is valid, enforceable, or infringed. Those questions are resolved through litigation or negotiated settlements (FDA, 2024).
Which companies are challenging dapagliflozin and saxagliptin patents?
Generic manufacturers typically challenge branded patents through Abbreviated New Drug Applications containing Paragraph IV certifications. The public record for these products has involved generic-drug companies seeking approval for dapagliflozin, saxagliptin, and related fixed-dose combinations.
The likely challenger profile includes large generic manufacturers such as Teva, Sandoz, Lupin, Sun Pharmaceutical, Dr. Reddy’s Laboratories, and other ANDA sponsors. The identity of the first filer matters because a successful first Paragraph IV filer may obtain 180 days of generic exclusivity under the Hatch-Waxman framework.
The commercial consequences differ by product:
- A successful dapagliflozin challenge can affect billions of dollars in annual Farxiga sales.
- A successful saxagliptin challenge affects a smaller and already declining revenue pool.
- A Qtern challenge may be constrained by the absence of broad commercial demand for the combination.
- A successful method-of-use challenge may permit a generic label with limited indications while leaving branded use protected in other indications.
What patent litigation and settlement risks affect these products?
Patent litigation risk is highest for Farxiga because its revenue base justifies substantial legal expenditure. AstraZeneca can seek damages, an injunction, or a negotiated entry date. Generic companies may challenge patent validity, claim construction, written description, obviousness, or infringement.
Settlement agreements can produce an authorized-generic strategy, a delayed generic entry date, or a license tied to manufacturing milestones. They can also preserve some revenue while permitting generic entry before all listed patents expire.
For saxagliptin, litigation economics are less favorable to the brand owner. The cost of defending a mature product can exceed the incremental value of delaying entry. AstraZeneca therefore has stronger incentives to manage the franchise through pricing, supply agreements, and portfolio rationalization than through prolonged litigation.
What formulation patents protect Qtern and other combinations?
Qtern combines dapagliflozin and saxagliptin in a single tablet. Qternmet XR adds metformin in an extended-release formulation. Potential protection can cover:
- The ratio of active ingredients.
- Tablet composition.
- Extended-release metformin technology.
- Manufacturing processes.
- Stability characteristics.
- Specific treatment methods.
Combination patents can delay a direct fixed-dose generic, but they do not necessarily prevent separate generic dapagliflozin and saxagliptin tablets from competing with the combination. Physicians can prescribe the agents separately, and payers often prefer the lowest-cost components.
This creates a structural weakness in Qtern’s commercial protection. The product can retain value through adherence and convenience, but its pricing ceiling is linked to the cost of its individual components.
What generic entry risks exist for dapagliflozin?
Generic dapagliflozin presents three principal risks.
First, payer substitution can be rapid. Pharmacy benefit managers may place generic dapagliflozin on preferred tiers soon after launch.
Second, price erosion may affect branded Farxiga before full generic entry. Payers can use anticipated competition to demand higher rebates.
Third, generic entry can expand total SGLT2 utilization while reducing AstraZeneca’s share. The class may continue to grow even as Farxiga revenue declines.
Farxiga’s cardiorenal indications may slow erosion because guideline-driven prescribing and specialist use are less price-sensitive than routine diabetes prescribing. The product’s revenue exposure is therefore likely to be segmented: diabetes sales face the fastest erosion, while heart-failure and kidney-disease sales may show greater brand persistence.
How does dapagliflozin compare with competing drugs?
| Drug |
Class |
Main commercial owner |
Competitive position |
| Dapagliflozin |
SGLT2 inhibitor |
AstraZeneca |
Strong cardiorenal profile and major growth franchise |
| Empagliflozin |
SGLT2 inhibitor |
Boehringer Ingelheim/Eli Lilly |
Major heart-failure and diabetes competitor |
| Canagliflozin |
SGLT2 inhibitor |
Johnson & Johnson/Mitsubishi Tanabe legacy franchise |
Established but less commercially dominant |
| Saxagliptin |
DPP-4 inhibitor |
AstraZeneca |
Mature, lower-growth oral diabetes product |
| Sitagliptin |
DPP-4 inhibitor |
Merck |
Historically leading DPP-4 product, now exposed to generic competition |
| Linagliptin |
DPP-4 inhibitor |
Boehringer Ingelheim/Eli Lilly |
Strong renal-dosing convenience and established use |
| Semaglutide |
GLP-1 receptor agonist |
Novo Nordisk |
High efficacy, weight-loss demand, injectable/oral expansion |
Dapagliflozin competes most directly with empagliflozin. The two products have similar cardiorenal positioning, and formulary outcomes often depend on rebate levels, contracting, and local guideline interpretation. Saxagliptin competes with generic DPP-4 agents and is less likely to regain premium positioning.
What is the biosimilar risk for dapagliflozin or saxagliptin?
There is no conventional biosimilar pathway risk because dapagliflozin and saxagliptin are small-molecule drugs, not biologics. The relevant threat is generic substitution through the Hatch-Waxman ANDA pathway.
This distinction matters commercially. Generic applicants do not need to reproduce the clinical-development program required for a biosimilar. Once regulatory and patent barriers are cleared, multiple manufacturers can enter with comparatively limited development costs.
What licensing deals shaped these products?
AstraZeneca and Bristol-Myers Squibb formed a diabetes alliance covering dapagliflozin and saxagliptin development and commercialization. AstraZeneca later assumed full ownership of the diabetes collaboration, including the associated products and rights, after acquiring Bristol-Myers Squibb’s interest in the alliance (AstraZeneca, 2014).
That transaction simplified control of Farxiga, Onglyza, and related combinations. It also concentrated the financial risk of patent expiry and generic competition at AstraZeneca.
What generic launch scenarios are most likely?
Scenario one: rapid commodity erosion
Several generic dapagliflozin manufacturers enter close together. Payers move quickly to generic substitution, and Farxiga diabetes revenue falls sharply within two to three years. Branded use persists mainly in specialist cardiorenal care.
Scenario two: staggered entry
One or two manufacturers enter under settlement terms. AstraZeneca retains meaningful branded revenue through contracting and indication-specific prescribing, while generic prices decline gradually.
Scenario three: delayed broad substitution
Patent litigation or regulatory disputes delay multiple ANDA approvals. Farxiga retains stronger revenue for longer, but payer pressure still increases as the expected entry date approaches.
For saxagliptin, the market is more likely to behave as a mature generic market. Volume may persist, but branded pricing and market share will remain under pressure.
Key Takeaways
- Dapagliflozin is the financially important asset; saxagliptin is a mature companion product.
- Farxiga revenue reached approximately $5.9 billion in 2023, supported by heart-failure and kidney-disease expansion.
- Onglyza and related saxagliptin products face class substitution, generic competition, and limited indication expansion.
- Farxiga faces meaningful U.S. generic-entry risk in the mid-2020s.
- Qtern’s combination protection is less durable commercially than Farxiga’s broader cardiorenal franchise.
- There is no biosimilar risk; generic ANDA competition is the relevant pathway.
- Dapagliflozin’s post-expiry erosion is likely to be fastest in diabetes and slower in specialist cardiorenal use.
- AstraZeneca’s acquisition of full rights from Bristol-Myers Squibb concentrated both the upside and the patent-expiry exposure.
FAQs About Dapagliflozin and Saxagliptin Hydrochloride
Is Qtern more commercially valuable than Onglyza?
No. Qtern benefits from dapagliflozin’s SGLT2 positioning, but Farxiga monotherapy and its cardiorenal indications are commercially more important. Onglyza remains a mature saxagliptin product with lower growth potential.
Does dapagliflozin patent expiry eliminate Farxiga sales?
No. Generic entry usually causes rapid price and volume erosion, but branded use can persist in specialist care, restricted formularies, and patients who remain stable on Farxiga.
Can generic dapagliflozin be substituted for all Farxiga uses?
Regulatory substitution depends on the approved generic labeling, state substitution rules, payer policy, and the scope of any remaining method-of-use patents. Approval of the active ingredient does not automatically resolve every patent or labeling issue.
Why has dapagliflozin grown while saxagliptin declined?
Dapagliflozin has gained evidence and approvals in heart failure and chronic kidney disease. Saxagliptin remains primarily a glucose-lowering drug and faces stronger competition from generic DPP-4 agents, SGLT2 inhibitors, and GLP-1 therapies.
Are fixed-dose combinations protected after the individual ingredients become generic?
They may retain product-specific patent protection, but separate generic ingredients can still compete economically. The strength of the combination franchise depends on adherence benefits, payer coverage, patent scope, and the availability of equivalent combinations.
References
-
AstraZeneca. (2014). AstraZeneca to acquire Bristol-Myers Squibb’s interests in diabetes alliance. AstraZeneca press release.
-
AstraZeneca. (2024). Annual report and Form 20-F for the year ended December 31, 2023. AstraZeneca PLC.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug product patents and exclusivity information. U.S. Department of Health and Human Services.
-
U.S. Patent and Trademark Office. (2024). Patent Center and patent litigation resources. U.S. Department of Commerce.
